非小细胞肺癌(NSCLC)仍然是全球人类癌症相关死亡的最常见原因。本研究旨在探讨长链非编码(lnc)RNAZEB2-AS1在NSCLC中的作用及相关机制。
进行定量实时聚合酶链反应以比较ZEB2-AS1在NSCLC癌组织和邻近的非肿瘤组织中的表达。还通过受试者工作特征曲线和Kaplan-Meier生存分析评估了ZEB2-AS1在NSCLC中的诊断和预后作用。用ZEB2-AS1siRNA转染NSCLC细胞系A549细胞,和细胞活力,迁移,入侵,比较ZEB2-AS1siRNA组和对照组的上皮间质转化(EMT)。
ZEB2-AS1在NSCLC组织中显著增加。ZEB2-AS1的敲低显著抑制了细胞活力,迁移,入侵,和体外A549细胞的EMT。
ZEB2-AS1在非小细胞肺癌中上调,它可以作为诊断的潜在目标,预后,和NSCLC的治疗。
Non-small cell lung cancer (NSCLC) remains the most common cause of human cancer-related death worldwide, and the present study aims to explore the roles of long non-coding (lnc)RNA ZEB2-AS1 in NSCLC and the related mechanism.
Quantitative real-time-polymerase chain reaction was performed to compare the expressions of ZEB2-AS1 in NSCLC cancer tissue and the adjacent non-tumorous tissues. The diagnostic and prognostic roles of ZEB2-AS1 in NSCLC were also evaluated by the receiver operating characteristic curve and the Kaplan-Meier survival analysis. NSCLC cell line A549 cells were transfected with ZEB2-AS1 siRNA, and the cell viability, migration, invasion, and epithelial-mesenchymal transition (EMT) of the ZEB2-AS1 siRNA group and control group were compared.
ZEB2-AS1 was significantly increased in NSCLC tissues. The knockdown of ZEB2-AS1 markedly inhibited the cell viability, migration, invasion, and EMT of A549 cells in vitro.
ZEB2-AS1 was up-regulated in NSCLC, and it may serve as a potential target for the diagnosis, prognosis, and treatment of NSCLC.